Research for the development of assessment strategy and treatment for cognitive impairment of Parkinson's disease

Neuroimaging study for the assessment and treatment of cognitive impairment of the patients with Parkinson's disease - RCIP-Nagoya Study: Research for the cognitive impairment of Parkinson's disease in Nagoya

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046104

Enrollment

Registered

2021-11-21

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

This study followed a randomized double-blind crossover design for the patients with mild cognitive impairments in PD. Patients in the memantine group were given memantine at 5 mg/day in the first wee

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Parkinson's disease who had confirmed clinical diagnosis using United Kingdom Parkinson's Disease Brain Bank Criteria .

Exclusion criteria

Exclusion criteria: Patients with dementia, or patients with abnormal findings of brain MRI except for PD, or patients using major psychotropic drugs, or patients with severe disturbance of hearing and/or eyesight.

Design outcomes

Primary

Measure	Time frame
BOLD signals of the rest and task conditions during scanning of functional MRI	—

Secondary

Measure	Time frame
Neuropsychological assessments	—

Countries

Japan

Contacts

Public ContactShoji Kawashima

Nagoya City University Department of neurology

shoji@med.nagoya-cu.ac.jp0528538093

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Research for the development of assessment strategy and treatment for cognitive impairment of Parkinson&#39;s disease